• 1
    Kumar R, Maillard I, Schuster DJ, et al. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am. 2004; 42: 10831100.
  • 2
    Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol. 2004; 126: 772784.
  • 3
    Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005; 104: 10661074.
  • 4
    Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 2001; 12: 825830.
  • 5
    Jerusalem G, Beguin Y. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma. 2002; 3: 5661.
  • 6
    Lu P. Staging and classification of lymphoma. Semin Nucl Med. 2005; 35: 160164.
  • 7
    Zinzani PL. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol. 2005; 32: 410.
  • 8
    O'Brien A, Del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995; 85: 307.
  • 9
    Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005; 80: 10871097.
  • 10
    Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
  • 11
    Schoder H, Noy A, Gonen M, et al. Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 46434651.
  • 12
    Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol. 2005; 23: 45774580.
  • 13
    Filmont J, KoYang F, Yap C, et al. Prediction of malignancy grade using 18FDG PET in non Hodgkin's lymphoma patients: an urban legend? J Nucl Med. 2002; 43: 79.
  • 14
    Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999; 94: 429433.
  • 15
    Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997; 15: 1587.
  • 16
    Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma after histologic conversion: A poor prognostic variant. Cancer Treat Rep. 1981; 65: 413.
  • 17
    Hicks RJ, Mac Manus MP Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med. 2005; 35: 165175.
  • 18
    The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood. 1997; 89: 39093918.
  • 19
    Rodriguez M, Rehn S, Ahlstrom H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med. 1995; 36: 17901796.
  • 20
    Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995; 86: 35223527.
  • 21
    Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of C-11 methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med. 1991; 32: 12111212.
  • 22
    Hoffman M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18 FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999; 10: 11851189.
  • 23
    Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005; 16: 473480.
  • 24
    Ha CS, Kong JS, McLaughlin P, et al. Stage III follicular lymphoma: long-term follow-up and patters of failure. Int J Radiat Oncol Biol Phys. 2003; 57: 748.
  • 25
    Xiao C, Su ZL, Wu QL, et al. Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi. 2005; 34: 2227.
  • 26
    Knowles DM. Neoplastic Hematopathology. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2001: 834.